{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:38:53Z","timestamp":1695555533796},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/kisup.2013.95","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T18:39:57Z","timestamp":1385577597000},"page":"457-461","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder"],"prefix":"10.1016","volume":"3","author":[{"given":"Shunsuke","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/kisup.2013.95_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2013.95_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10754-007-9017-8","article-title":"The organization and financing of end-stage renal disease treatment in Japan","volume":"7","author":"Fukuhara","year":"2007","journal-title":"Int J Health Care Finance Econ"},{"key":"10.1038\/kisup.2013.95_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4009\/jsdt.46.1","article-title":"Overview of regular dialysis treatment in Japan (as of December 31, 2011)","volume":"46","author":"Nakai","year":"2013","journal-title":"J Jpn Soc Dial Ther"},{"key":"10.1038\/kisup.2013.95_bb0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1524-4733.2005.00049.x","article-title":"Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis","volume":"8","author":"Huybrechts","year":"2005","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0030","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/ndt\/gfm367","article-title":"Economic evaluation of sevelamer in patients with end-stage renal disease","volume":"22","author":"Manns","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/kisup.2013.95_bb0035","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079908X260853","article-title":"An economic evaluation of sevelamer in patients new to dialysis","volume":"24","author":"Taylor","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1038\/kisup.2013.95_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1524-4733.2008.00408.x","article-title":"Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences","volume":"12","author":"Huybrechts","year":"2009","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0045","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3111\/13696998.2013.792267","article-title":"Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom","volume":"16","author":"Thompson","year":"2013","journal-title":"J Med Econ"},{"key":"10.1038\/kisup.2013.95_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.718019","article-title":"A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom","volume":"16","author":"Bernard","year":"2013","journal-title":"J Med Econ"},{"key":"10.1038\/kisup.2013.95_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1524-4733.2006.00142.x","article-title":"The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease","volume":"10","author":"Brennan","year":"2007","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jval.2011.05.005","article-title":"Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis","volume":"14","author":"Vegter","year":"2011","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0065","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.clinthera.2012.06.006","article-title":"Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective","volume":"34","author":"Vegter","year":"2012","journal-title":"Clin Ther"},{"key":"10.1038\/kisup.2013.95_bb0070","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2011.05.043","article-title":"Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective","volume":"14","author":"Park","year":"2011","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0075","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/ndt\/gfl774","article-title":"The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective","volume":"22","author":"Garside","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/kisup.2013.95_bb0080","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1524-4733.2008.00329.x","article-title":"Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA","volume":"11","author":"Ray","year":"2008","journal-title":"Value Health"},{"key":"10.1038\/kisup.2013.95_bb0085","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11538600-000000000-00000","article-title":"Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy","volume":"28","author":"Eandi","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1038\/kisup.2013.95_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3111\/13696998.2012.664799","article-title":"Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States","volume":"15","author":"Boer","year":"2012","journal-title":"J Med Econ"},{"key":"10.1038\/kisup.2013.95_bb0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00044011-200626110-00002","article-title":"Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis","volume":"26","author":"Rosery","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1038\/kisup.2013.95_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1185\/03007990902844097","article-title":"Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective","volume":"25","author":"Nuijten","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1038\/kisup.2013.95_bb0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11536310-000000000-00000","article-title":"Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model","volume":"30","author":"Nuijten","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1038\/kisup.2013.95_bb0110","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2215\/CJN.08841010","article-title":"Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan","volume":"6","author":"Goto","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/kisup.2013.95_bb0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.ajkd.2011.12.034","article-title":"Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan","volume":"60","author":"Komaba","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/kisup.2013.95_bb0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1038\/kisup.2013.95_bb0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2013.95_bb0130","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2013.95_bb0135","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2013.95_bb0140","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2013.95_bb0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/kisup.2013.95_bb0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.ajkd.2007.03.009","article-title":"Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis","volume":"49","author":"Narayan","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/kisup.2013.95_bb0155","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171615311898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171615311898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:54:49Z","timestamp":1626872089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171615311898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S2157171615311898"],"URL":"https:\/\/doi.org\/10.1038\/kisup.2013.95","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}